Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
David J. Wambeke Insider Profile
4 Followers
David J. Wambeke, CBO at Diamedica Therapeutics, holds 527.11K shares in Diamedica Therapeutics (Ticker: DMAC). Most recently, David J. Wambeke Bought $20,000 shares of Diamedica Therapeutics on Nov 16, 2023 for an estimated value of 49.20K.
Profitable Transactions
2 out of 3 Profitable Transactions
Average Return
+16.90%
Average return per transaction
Time Frame
Compare to
Insider Holdings
100.00%
A breakdown of David J. Wambeke's holdings
Insider Roles
CBO
Roles that David J. Wambeke holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Buy
Date:Apr 11, 2023 - Apr 11, 2024
Return:+56.70%
The most profitable trade made by David J. Wambeke
David J. Wambeke's Trading History
List of latest transactions for each holding click on a transaction to see David J. Wambeke's performance on stock
You May Also Like
David J. Wambeke insider profile FAQ
What is the percentage of profitable transactions made by David J. Wambeke?
The percentage of profitable transactions made by David J. Wambeke is 67%.
What is the average return per transaction made by David J. Wambeke?
The average return per transaction made by David J. Wambeke is 16.90%.
What stocks does David J. Wambeke hold?
David J. Wambeke holds: DMAC stocks.
What was David J. Wambeke’s latest transaction?
David J. Wambeke latest transaction was an Informative Buy of $49.20K.
What was David J. Wambeke's most profitable transaction?
David J. Wambeke’s most profitable transaction was an Informative Buy of DMAC stock on April 11, 2023. The return on the trade was 56.70%.
What is David J. Wambeke's role in Diamedica Therapeutics?
David J. Wambeke's role in Diamedica Therapeutics is CBO.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.